BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yang XL, Shi Y, Zhang DD, Xin R, Deng J, Wu TM, Wang HM, Wang PY, Liu JB, Li W, Ma YS, Fu D. Quantitative proteomics characterization of cancer biomarkers and treatment. Mol Ther Oncolytics 2021;21:255-63. [PMID: 34095463 DOI: 10.1016/j.omto.2021.04.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Dunphy K, O'Mahoney K, Dowling P, O'Gorman P, Bazou D. Clinical Proteomics of Biofluids in Haematological Malignancies. Int J Mol Sci 2021;22:8021. [PMID: 34360786 DOI: 10.3390/ijms22158021] [Reference Citation Analysis]
2 Wang T, Denman D, Bacot SM, Feldman GM. Challenges and the Evolving Landscape of Assessing Blood-Based PD-L1 Expression as a Biomarker for Anti-PD-(L)1 Immunotherapy. Biomedicines 2022;10:1181. [DOI: 10.3390/biomedicines10051181] [Reference Citation Analysis]
3 Wang J, Ye T, Wang S, Wang J, Jin Y. Molecular mechanisms and therapeutic relevance of gasdermin E in human diseases. Cell Signal 2021;90:110189. [PMID: 34774988 DOI: 10.1016/j.cellsig.2021.110189] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Xian R, Wang C, Gong L, Hang B, Wang W, Zhang X, Du H, Wang F, Shi F. A Species-Specific Strategy for the Identification of Hemocoagulase Agkistrodon halys pallas Based on LC-MS/MS-MRM. Front Mol Biosci 2022;9:831293. [DOI: 10.3389/fmolb.2022.831293] [Reference Citation Analysis]